Related Experiment Video
Updated: Nov 6, 2025
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
Nadia Hindi1, Javier Martin-Broto
1Oncology Department, Fundacion Jimenez Diaz University Hospital, Av Reyes Catolicos 2, 28040 Madrid (Spain)/Villalba University Hospital/Rey Juan Carlos I University Hospital/Infanta Elena University Hospital and Research Institute FJD-UAM, Madrid (Spain) and ATBsarc, CITIUS III, Seville, Spain.
Purpose Of Review:
The aim is to bring latest evidence of the role of perioperative chemotherapy in localized soft-tissue sarcomas (STS) of limbs and to review the risk classification systems of retroperitoneal and extremity STS.
Recent Findings:
High-risk subset of localized STS of limbs and trunk-wall, defined with classic prognostic factors, consistently obtained 5-year overall survival ranging from 69 to 76% in randomized patients treated with full-dose of anthracycline and ifosfamide. Validated nomograms accurately predict, on individual basis, the risk of death and recurrence in localized STS of retroperitoneum and limbs, enabling a better selection of high-risk patients (usually those with death risk of ≥40%) that potentially could benefit with perioperative systemic treatment. Nomograms have virtually converted a negative large perioperative trial into a positive, favouring chemotherapy arm in the high-risk selection.
Summary:
Perioperative three cycles of full-dose of anthracycline and ifosfamide should be proposed on an individual basis, in reference sarcoma centres, to high-risk localized STS of limbs or trunk-wall in certain histologies.
